Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06716307 · ClinicalTrials.gov registry record · Phase 1
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT06716307 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 18 participants.
The verdict
NCT06716307, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe. Participants will get an injection with each of the two versions of CagriSema at two different times at the clinic. Like all medicines, the study medicine may have side effects. The study will last for about 18 weeks.
Interventions
- DRUG CagriSema (cagrilintide B and semaglutide I)
- DRUG CagriSema A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06716307
The ClinicalTrials.gov registry entry for NCT06716307 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CagriSema (cagrilintide B and semaglutide I) is the first listed.
NCT06716307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06716307 about?
NCT06716307 is a clinical study titled "A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity". This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for docto...
What is the current status of trial NCT06716307?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-12-02. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT06716307?
The interventions under investigation include: CagriSema (cagrilintide B and semaglutide I) (DRUG), CagriSema A (DRUG).
Who is sponsoring clinical trial NCT06716307?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.